Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
65.750
Open
64.800
VWAP
62.74
Vol
11.19M
Mkt Cap
10.84B
Low
60.920
Amount
701.72M
EV/EBITDA(TTM)
--
Total Shares
173.12M
EV
11.80B
EV/OCF(TTM)
--
P/S(TTM)
11.80
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.
Show More
10 Analyst Rating
-2.56% Downside
Wall Street analysts forecast TEM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 61.00 USD with a low forecast of 48.00 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
5 Hold
0 Sell
Moderate Buy
-2.56% Downside
Current: 62.600
Low
48.00
Averages
61.00
High
74.00
-2.56% Downside
Current: 62.600
Low
48.00
Averages
61.00
High
74.00
Piper Sandler
David Westenberg
Hold
Maintains
$55 → $70
2025-05-15
New
Reason
Piper Sandler
David Westenberg
Price Target
$55 → $70
2025-05-15
New
Maintains
Hold
Reason
Morgan Stanley
Tejas Savant
Buy
Maintains
$60 → $65
2025-05-09
Reason
Morgan Stanley
Tejas Savant
Price Target
$60 → $65
2025-05-09
Maintains
Buy
Reason
Needham
Ryan MacDonald
Strong Buy
Reiterates
$70
2025-04-24
Reason
Needham
Ryan MacDonald
Price Target
$70
2025-04-24
Reiterates
Strong Buy
Reason
BTIG
Mark Massaro
Strong Buy
Initiates
$60
2025-04-21
Reason
BTIG
Mark Massaro
Price Target
$60
2025-04-21
Initiates
Strong Buy
Reason
BTIG initiated coverage of Tempus AI with a Buy rating and $60 price target.
Needham
Ryan MacDonald
Strong Buy
Reiterates
$70
2025-04-10
Reason
Needham
Ryan MacDonald
Price Target
$70
2025-04-10
Reiterates
Strong Buy
Reason
Morgan Stanley
Tejas Savant
Buy
Maintains
$50 → $60
2025-03-06
Reason
Morgan Stanley
Tejas Savant
Price Target
$50 → $60
2025-03-06
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tempus AI Inc (TEM.O) is -89.33, compared to its 5-year average forward P/E of -62.76. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-62.76
Current PE
-89.33
Overvalued PE
-33.66
Undervalued PE
-91.86
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
22.34
Current EV/EBITDA
-2912.54
Overvalued EV/EBITDA
1143.71
Undervalued EV/EBITDA
-1099.03
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
8.42
Current PS
8.50
Overvalued PS
10.21
Undervalued PS
6.63
Financials
Annual
Quarterly
FY2025Q1
YoY :
+75.38%
255.74M
Total Revenue
FY2025Q1
YoY :
-25.06%
-40.37M
Operating Profit
FY2025Q1
YoY :
+5.09%
-68.04M
Net Income after Tax
FY2025Q1
YoY :
-28.57%
-0.40
EPS - Diluted
FY2025Q1
YoY :
+1.40%
-109.00M
Free Cash Flow
FY2025Q1
YoY :
+13.91%
60.69
Gross Profit Margin - %
FY2025Q1
YoY :
-47.60%
-26.47
FCF Margin - %
FY2025Q1
YoY :
-40.09%
-26.60
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
50.2M
USD
19
3-6
Months
501.9M
USD
56
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
17.8M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
150.0K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
150.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
11
17.4M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
75.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
50.2M
USD
19
3-6
Months
501.9M
USD
56
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
17.8M
USD
Months
TEM News & Events
Events Timeline
2025-05-14 (ET)
2025-05-14
08:39:28
Tempus AI enters collaboration to advance Boehringer Ingelheim's cancer pipeline
2025-05-06 (ET)
2025-05-06
16:03:29
Tempus AI raises FY25 revenue view to roughly $1.25B from $1.24B
2025-05-06
16:02:29
Tempus AI reports Q1 adjusted EPS (24c), consensus (27c)
Sign Up For More Events
Sign Up For More Events
News
3.0
05-15NASDAQ.COMAfter 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?
7.5
05-14NewsfilterTempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
7.5
05-14SeekingAlphaTempus partners with Boehringer Ingelheim to develop cancer treatments
Sign Up For More News
People Also Watch
THO
Thor Industries Inc
81.500
USD
-0.01%
UBSI
United Bankshares Inc
37.320
USD
+0.81%
PIPR
Piper Sandler Companies
265.460
USD
+0.22%
CYTK
Cytokinetics Inc
29.840
USD
-0.53%
VIST
Vista Energy SAB de CV
50.560
USD
-1.62%
BE
Bloom Energy Corp
19.820
USD
-2.12%
GATX
GATX Corp
150.030
USD
+0.68%
USM
United States Cellular Corp
61.030
USD
+1.13%
PFSI
PennyMac Financial Services Inc
100.760
USD
+2.00%
IBP
Installed Building Products Inc
162.530
USD
-0.40%
FAQ
What is Tempus AI Inc (TEM) stock price today?
The current price of TEM is 62.6 USD — it has decreased -3.37 % in the last trading day.
What is Tempus AI Inc (TEM)'s business?
What is the price predicton of TEM Stock?
What is Tempus AI Inc (TEM)'s revenue for the last quarter?
What is Tempus AI Inc (TEM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tempus AI Inc (TEM)'s fundamentals?
How many employees does Tempus AI Inc (TEM). have?